BAVARIAN NORDIC WKN: 917165 ISIN: DK0015998017 Kürzel: 0DPB Forum: Aktien Thema: Hauptdiskussion

Montag sehen wir dir 50,xx €

Du, das war schon vor 4 Tagen.

☕👍

https://www.presseportal.de/pm/14407/5284438

https://www.finanzen.net/nachricht/aktien/genehmigung-bavarian-nordic-aktie-gewinnt-eu-kommission-hat-bavarian-nordic-impfstoff-imvanex-gegen-affenpocken-zugelassen-11560490

Moin moin 🙋‍♂️ Genehmigung: Bavarian Nordic-Aktie gewinnt: EU-Kommission hat Bavarian Nordic-Impfstoff Imvanex gegen Affenpocken zugelassen | Nachricht | finanzen.net

Bavarian Nordic, das vor kurzem die Zulassung für seinen Affenpocken-Impfstoff erhalten hat, erhielt von der FDA und der EU behördliche Zustimmungen, um mit der Produktion der Impfung in seiner Fill-Finish-Anlage in Dänemark zu beginnen. Wenn diese regulatorischen Kästchen abgehakt sind, kann Bavarian Nordic mit der Herstellung und Lieferung seiner Behandlung – in den USA als Jynneos bekannt – aus seinen eigenen Anlagen beginnen. Zuvor wurde der Impfstoff von einem namentlich nicht genannten Auftragshersteller hergestellt. FDA-Inspektoren führten Anfang Juli eine Vorabinspektion der Anlage durch.

Genießen und schweigen

Ja, ich bin selbst im 100 Ptozent im Plus. Trotzdem sollte man nicht zu viel erwarten. Die 50 in 3 Jahren wären für mich aber völlig in Ordnung.

Also für die gute Performance wird hier erstaunlich wenig geredet 🤣aber besser so, als die ständigen Basher

Und obwohl es kein Corona ist. Kurs um gut 160% hoch in drei Monaten. Was will ma da noch sagen... Bei Valneva läuft es deutlich schlechter 😂🙈 freut euch...

In welchem Zritraum ? In 2 Jahren vielleicht, das hängt auch von der Ausbreitung der Affenpocken ab. Das hier idt nicht Corona.

Ob die 50 geknackt wird?

Doch jetzt… aber falsche Richtung 🙈📉

Der Kurs bewegt sich kein Stück

The Biden administration privately estimated to Congress this month that it may need nearly $7 billion to mount a response to the nation’s monkeypox outbreak that matches “the scope and urgency of the current situation.” The funding estimate, the details of which were contained in a memo addressed to President Biden and obtained by The Washington Post, reflected early talks among congressional Democrats and White House officials in pursuit of a spending package that could boost the availability of monkeypox tests, vaccine doses and treatments. The amount did not mark a formal request for aid to Congress. Rather, it was one of a series of options reflecting various amounts that could fund varying levels of federal mitigation efforts. White House aides recently presented the ideas at the request of Democratic leaders on the Senate’s top health-focused committee, according to the memo. A Democratic aide, who spoke on the condition of anonymity to describe the private conversations, confirmed the funding details to The Post. According to the memo obtained by The Post, officials estimate that $6.9 billion in new funding for the monkeypox response would allow the Department of Health and Human Services to support “domestic end-to-end vaccine manufacturing capacity and technology transfer” in the United States. The only vaccine specifically approved by the Food and Drug Administration for monkeypox, Jynneos, is produced in Denmark, which has caused significant complications in the U.S. response — for instance, hundreds of thousands of Jynneos doses were stranded overseas for weeks, awaiting U.S. inspection and transport. With that much funding, officials further estimate that they would be able to secure 19 million new doses of vaccine for monkeypox and replenish about 4 million doses for paused smallpox preparedness efforts, as well as purchase more antiviral treatments, expand testing, improve vaccine distribution, and provide coverage of services for uninsured and underinsured Americans, among other goals. Health officials also estimated the effects of a “medium” second option, seeking $2.2 billion in monkeypox funding to purchase some vaccine doses and treatments that would be targeted toward the gay and bisexual community, where the outbreak is currently concentrated. But the amount may only provide an effective response if the outbreak remains contained and does not spill into broader populations, “which is not guaranteed,” the memo cautions. Officials also estimated a bare-bones fallback option of $500 million that would allow for purchasing some vaccine doses and continuing “minimal” operations. Health officials have said they are funding the current monkeypox response by drawing on existing appropriations and a response fund maintained by the Centers for Disease Control and Prevention. The Biden administration has distributed 330,000 vaccine doses and contracted for a total of 6.9 million Jynneos doses by mid-2023, in addition to other investments in tests and treatments.